Signaturefd LLC Decreases Stock Position in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)

Signaturefd LLC cut its position in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) by 45.6% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,078 shares of the company’s stock after selling 1,745 shares during the period. Signaturefd LLC’s holdings in Syndax Pharmaceuticals were worth $27,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also recently made changes to their positions in the company. AlphaQuest LLC lifted its holdings in Syndax Pharmaceuticals by 32.3% in the 4th quarter. AlphaQuest LLC now owns 23,623 shares of the company’s stock valued at $312,000 after purchasing an additional 5,765 shares in the last quarter. E Fund Management Co. Ltd. lifted its stake in shares of Syndax Pharmaceuticals by 14.4% in the fourth quarter. E Fund Management Co. Ltd. now owns 12,603 shares of the company’s stock worth $167,000 after buying an additional 1,583 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its stake in shares of Syndax Pharmaceuticals by 1.3% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 704,823 shares of the company’s stock worth $9,318,000 after buying an additional 8,876 shares in the last quarter. Cape Investment Advisory Inc. boosted its position in Syndax Pharmaceuticals by 157.1% during the fourth quarter. Cape Investment Advisory Inc. now owns 6,427 shares of the company’s stock worth $85,000 after acquiring an additional 3,927 shares during the last quarter. Finally, Bank of New York Mellon Corp grew its stake in Syndax Pharmaceuticals by 1.2% during the 4th quarter. Bank of New York Mellon Corp now owns 224,261 shares of the company’s stock valued at $2,965,000 after acquiring an additional 2,759 shares in the last quarter.

Wall Street Analyst Weigh In

SNDX has been the topic of a number of research reports. Citigroup decreased their target price on shares of Syndax Pharmaceuticals from $45.00 to $42.00 and set a “buy” rating on the stock in a research note on Tuesday, March 4th. JPMorgan Chase & Co. increased their price target on Syndax Pharmaceuticals from $39.00 to $41.00 and gave the company an “overweight” rating in a report on Thursday, March 20th. Scotiabank lowered their price objective on Syndax Pharmaceuticals from $18.00 to $16.00 and set a “sector perform” rating on the stock in a research note on Wednesday, January 8th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $51.00 target price on shares of Syndax Pharmaceuticals in a research note on Tuesday, March 4th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and nine have given a buy rating to the company. According to data from MarketBeat, Syndax Pharmaceuticals presently has an average rating of “Moderate Buy” and an average price target of $36.20.

Syndax Pharmaceuticals Stock Down 2.1 %

NASDAQ:SNDX opened at $13.44 on Wednesday. Syndax Pharmaceuticals, Inc. has a 52 week low of $12.06 and a 52 week high of $25.07. The stock’s fifty day moving average is $14.28 and its two-hundred day moving average is $15.98. The company has a market capitalization of $1.16 billion, a P/E ratio of -3.70 and a beta of 0.92.

Syndax Pharmaceuticals (NASDAQ:SNDX) last issued its quarterly earnings data on Monday, March 3rd. The company reported ($1.10) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.31) by ($0.79). The company had revenue of $7.68 million for the quarter, compared to analysts’ expectations of $86.32 million. Sell-side analysts anticipate that Syndax Pharmaceuticals, Inc. will post -3.72 earnings per share for the current fiscal year.

Insider Activity

In related news, insider Neil Gallagher sold 4,618 shares of Syndax Pharmaceuticals stock in a transaction that occurred on Monday, February 10th. The shares were sold at an average price of $15.50, for a total value of $71,579.00. Following the completion of the sale, the insider now owns 85,095 shares in the company, valued at approximately $1,318,972.50. This trade represents a 5.15 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Michael A. Metzger sold 13,288 shares of the company’s stock in a transaction on Monday, February 10th. The stock was sold at an average price of $15.50, for a total value of $205,964.00. Following the transaction, the chief executive officer now owns 300,121 shares in the company, valued at $4,651,875.50. This trade represents a 4.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 21,683 shares of company stock valued at $336,087. Company insiders own 4.10% of the company’s stock.

Syndax Pharmaceuticals Company Profile

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).